Genentech, a member of the Roche Group, announced that results from the ADACTA study will be presented on November 11 during an oral presentation at the 2012 American College of Rheumatology (ACR) Annual Scientific Meeting in Washington, D.C.
Results from the study showed Actemra (tocilizumab) improved signs and symptoms (DAS28 score reduction) of rheumatoid arthritis (RA) significantly more than adalimumab when used alone as a single-agent therapy (without other disease-modifying antirheumatic drugs (DMARDs), including methotrexate).
RA patients are often treated with a combination of medicines that typically include a biologic medicine, such as Actemra or adalimumab, plus methotrexate. However, about one in three patients on a biologic treatment such as Actemra or adalimumab receive it as a single-agent therapy, largely due to intolerance to methotrexate.
"The goal of the ADACTA study was to evaluate the potential differences of Actemra versus Humira when used as single-agent therapies for people with RA," said Hal Barron, M.D., chief medical officer and head, Global Product Development. "Data being presented at ACR further support the efficacy and safety profile of Actemra."
In addition to data from the ADACTA study, long-term follow-up of patients from AMBITION, a large Phase 3 study, will be presented at ACR. Together, these studies support the use of Actemra alone as a single-agent therapy for RA patients who are either intolerant to methotrexate or in whom methotrexate use would not be appropriate.
Date: November 10, 2012